Condition: Biliary Tract Cancer · Sponsor: AstraZeneca
The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Birmingham, Alabama, United States | Not Yet Recruiting |
| Research Site | Phoenix, Arizona, United States | Recruiting |
| Research Site | Tucson, Arizona, United States | Recruiting |
| Research Site | Duarte, California, United States | Recruiting |
| Research Site | Orange, California, United States | Recruiting |
| Research Site | Palo Alto, California, United States | Recruiting |
| Research Site | Santa Monica, California, United States | Not Yet Recruiting |
| Research Site | Aurora, Colorado, United States | Recruiting |
| Research Site | Hartford, Connecticut, United States | Not Yet Recruiting |
| Research Site | New Haven, Connecticut, United States | Recruiting |
| Research Site | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| Research Site | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
+ 162 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07221253